Mechanisms and treatment of resistant hypertension

Journal of Clinical Hypertension

Volumn 10, Issue 3, 2008, Pages 239-244

  Pimenta, Eduardo ^a   Gaddam, Krishna K ^a   Oparil, Suzanne ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANTIHYPERTENSIVE AGENT; SPIRONOLACTONE;

ARTICLE; COMORBIDITY; DRUG COMBINATION; DRUG RESISTANCE; HUMAN; HYPERTENSION; RISK FACTOR;

ALDOSTERONE ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; COMORBIDITY; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RISK FACTORS; SPIRONOLACTONE;

EID: 43549105386     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.08143.x     Document Type: Article

References (15)

1. Calhoun DA. Resistant or difficult-to-treat hypertension. J Clin Hypertens (Greenwich). 2006;8:181-186.
2. Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease: Why is it so resistant to treatment? Kidney Int. 2006;69:967-973.
3. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839-845.
4. Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
5. Cushman WC, Ford CE, Cutler JA, et al; ALLHA T Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404.
6. Haddy FJ. Role of dietary salt in hypertension. Life Sci. 2006;79:1585-1592.
7. Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000;36:594-599.
8. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19:2271-2277.
9. Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the healthy people 2010 blood pressure control goals. Hypertension. 2006;47:345-351.
10. Pimenta E, Calhoun DA. Primary aldosteronism: diagnosis and treatment. J Clin Hypertens (Greenwich). 2006;8:887-893.
11. Roumie CL, Elasy TA, Greevy R, et al. Improving blood pressure control through provider education, provider alerts, and patient education. Ann Intern Med. 2006;145:165-175.
12. White WB. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension. 2007;49:408-418.
13. Sowers JR, White WB, Pitt B, et al; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. The effects of cyclooxygenase- 2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis and type 2 diabetes. Arch Intern Med. 2005;165(2):161-168.
14. Nishizaka MK, Pratt-Ubunama M, Zaman MA, et al. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens. 2005;18(6):805-812.
15. Pimenta E, Calhoun DA. Resistant hypertension and aldosteronism. Curr Hypertens Rep. 2007;9(5):353-359.